Yogi receives Rs 46.21 crore purchase orders from Companion Vinimay Trading
Yogi Limited announced on Monday (July 21, 2025) that it has secured fresh purchase orders worth approximately ₹46.21 crore from Companion Vinimay Trading Private Limited. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
According to the company's filing with BSE, the orders cover the supply and delivery of a complete set of industrial equipment, which includes: Structure Assembly
Head Assembly
Rotary Table & Electrical Accessories
Tool Changer & Additional Axis
Accessories
The company informed that the purchase orders were awarded by a domestic entity and are expected to be executed within approximately 15 days. The orders carry standard terms relating to quality, delivery schedule, and mutually agreed pricing. Yogi Limited also clarified that neither the promoter group nor related parties have any interest in the contracting entity, and the transaction does not qualify as a related party transaction.
The order value of ₹46.21 crore is exclusive of taxes.
Commenting on the development, Managing Director Ghanshyambhai Nanjibhai Patel signed off the announcement from the company's Mumbai office, indicating the company's commitment to timely execution.
This order strengthens Yogi Limited's industrial equipment segment and is expected to contribute positively to its near-term revenues.
Disclaimer: The information provided is based on company filings and is intended for informational purposes only. Investors are advised to do their own research or consult a financial advisor before making any investment decisions. Neither the author nor the publisher is responsible for any actions taken based on this information.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Dr. Reddy's shares jump over 3% following Q1 results – Should you buy, hold or sell? Know More
By Aditya Bhagchandani Published on July 24, 2025, 09:37 IST Shares of Dr. Reddy's Laboratories surged 3.06% to Rs 1,285.60 on Wednesday after the company reported its Q1 FY26 financial results. The stock touched an intraday high of Rs 1,287.90 and now commands a market capitalization of Rs 1.07 lakh crore. For the quarter ended June 30, 2025, the pharmaceutical major posted a consolidated net profit of Rs 1,418 crore, up 2% year-on-year. Revenue from operations stood at Rs 8,545 crore, reflecting an 11% YoY increase, primarily driven by contributions from the acquired Nicotine Replacement Therapy (NRT) portfolio and steady performance in branded markets. However, profit declined 11% quarter-on-quarter, while revenue remained flat sequentially. EBITDA for the quarter was Rs 2,280 crore, marking a 5% YoY increase, though EBITDA margin slipped 530 basis points to 56.9%, largely due to pricing pressure in the US generics segment and lower operating leverage. The Global Generics segment recorded Rs 7,560 crore in revenue, up 10% YoY, but remained unchanged QoQ. Revenue from North America declined 11% YoY to Rs 3,410 crore amid price erosion in key generics like Lenalidomide. Meanwhile, India revenue grew 11% YoY to Rs 1,470 crore, aided by new launches and pricing strategies. European business saw a sharp 142% YoY jump to Rs 1,270 crore, driven by the NRT acquisition and product launches. Brokerages offered a cautious outlook on Dr. Reddy's Laboratories following its Q1 FY26 results, primarily due to concerns over the US generics business. CLSA and Jefferies both retained their 'Underperform' ratings, with target prices of Rs 1,120 and Rs 1,100 respectively. CLSA noted that while overall earnings were in line with expectations, the US base business is expected to remain flat or grow in low single digits year-on-year, with Revlimid sales likely tapering off from Q3FY26. Jefferies flagged a miss in Q1 estimates due to a sharper-than-expected decline in US sales, driven by lower revenues from gRevlimid and sustained pressure in the base portfolio. Elevated SG&A and R&D spending also weighed on margins. However, it highlighted upcoming launches such as gOzempic in Canada and the US filing for Abatacept as key triggers to watch. Meanwhile, Morgan Stanley maintained an 'Equal-weight' rating with a target price of Rs 1,298, acknowledging steady growth in most markets but citing generic price erosion and reduced operating leverage as drag factors on margin. Dr. Reddy's Q1 YoY Comparison Table (in Rs crore): Metric Q1 FY26 Q1 FY25 YoY % Change Revenue from Operations 8,545 7,700 11% Net Profit 1,418 1,390 2% EBITDA 2,280 2,170 5% EBITDA Margin (%) 56.9% 62.2% -530 bps Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
an hour ago
- Business Upturn
Force Motors shares surge 13% as Q1 net profit jumps 52% YoY; Anshul Saxena appointed VP of strategy
By Aditya Bhagchandani Published on July 24, 2025, 09:39 IST Shares of Force Motors surged over 13% to Rs 19,371 on Wednesday after the company reported a 52.3% year-on-year rise in consolidated net profit at Rs 176.3 crore for Q1FY26, up from Rs 115.7 crore in the year-ago period. The strong earnings were driven by double-digit growth in both revenue and operating margins. Force Motors' revenue from operations grew 21.9% YoY to Rs 2,297 crore, compared to Rs 1,885 crore in Q1FY25. On the operating front, EBITDA stood at Rs 332 crore, rising 33.3% from Rs 249 crore a year earlier. The EBITDA margin expanded to 14.4%, up from 13.2%, reflecting improved operating efficiency and stronger volumes. The stock touched a high of Rs 19,198 during the session, marking a fresh 52-week high. As of the latest update, the company's market capitalization stood at Rs 25,003 crore. The day's trading range was between Rs 17,225 and Rs 19,198. Additionally, the company announced a key leadership appointment. Anshul Saxena has joined Force Motors as Vice President – Corporate Strategy, effective July 23. Backed by over 19 years of cross-functional leadership experience, Saxena is expected to spearhead the company's long-term growth roadmap and strategic partnerships. His appointment was approved by the board based on recommendations from the Nomination & Remuneration Committee. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
an hour ago
- Business Upturn
Tilaknagar Industries shares rise over 2% as it acquires Imperial Blue from Pernod Ricard for Rs 4,150 crore
By Aditya Bhagchandani Published on July 24, 2025, 09:33 IST Shares of Tilaknagar Industries surged over 2% to Rs 483.00 in early trade on Wednesday after the company signed a definitive agreement to acquire the Imperial Blue business from Pernod Ricard at an enterprise value of Rs 4,150 crore. The previous close stood at Rs 473.25, and the stock touched an intraday high of Rs 496.50. At 9:30 AM, the company's market capitalization stood at Rs 93,910 crore, with a price-to-earnings (P/E) ratio of 40.78. The year range for the stock is between Rs 199.53 and Rs 496.50, indicating strong momentum in recent months. The acquisition marks a significant milestone for Tilaknagar Industries, strengthening its footprint in the Indian spirits market. Imperial Blue, a major brand in the value segment, was part of Pernod Ricard's India business. The divestiture is expected to be immediately accretive to Pernod Ricard's operating margins and net sales growth. Pernod Ricard stated that this move is part of its premiumization strategy in India, focusing on brands like Royal Stag, Blenders Pride, Chivas, Jameson, and Absolut. The company plans to streamline operations and concentrate on high-margin products. This acquisition is pending regulatory approval from the Competition Commission of India and is expected to close in the coming months. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
